Cargando…
Experience of an academic institute in importing a novel preclinical drug into India
The article throws light on the process of importing a novel preclinical drug into India based on the real-life experience from one of our studies. A novel drug “X” acting through a new mechanism of action was hypothesized by us to function as a neuroprotectant. It was decided to import this novel d...
Autores principales: | Kumar, M. Praveen, Medhi, Bikash |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754941/ https://www.ncbi.nlm.nih.gov/pubmed/29326494 http://dx.doi.org/10.4103/ijp.IJP_292_17 |
Ejemplares similares
-
Reporting of adverse events related to medical devices: A single-center experience from a tertiary care institute of national importance in India
por: Meher, Bikash Ranjan, et al.
Publicado: (2023) -
Developing and sustaining India's capacity for preclinical drug discovery
por: Lewis, David I., et al.
Publicado: (2018) -
Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India
por: Kumar, Vipin, et al.
Publicado: (2018) -
Identifying barriers to report adverse drug reactions using the Delphi method: Experience from an institute of national importance of India
por: Meher, Bikash Ranjan, et al.
Publicado: (2022) -
Materiovigilance Programme of India: Current status and way forward
por: Saifuddin, P. K., et al.
Publicado: (2022)